{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007664","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.419655+00:00","generated_at":"2026-05-21T08:24:04.698024+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"KALA BIO Q1 net loss $8.9M; cash $42.2M; KPI-012 Phase 2b topline data due Q3 2025","bullets":["Cash and cash equivalents of $42.2M as of March 31, 2025, expected to fund operations into Q1 2026.","Q1 2025 net loss $8.9M ($1.41 per diluted share) vs $11.8M ($4.20) prior year; operating loss $10.7M.","G&A $4.6M (down from $5.4M); R&D $6.1M (down from $6.4M). Weighted shares 6.3M vs 2.8M.","Phase 2b CHASE trial of KPI-012 in PCED continues enrolling; topline data anticipated in Q3 2025.","Exploring KPI-012 for Limbal Stem Cell Deficiency; preclinical KPI-014 for inherited retinal diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007664","json":"https://secwatch.observer/filing/0001558370-25-007664.json","markdown":"https://secwatch.observer/filing/0001558370-25-007664.md","text":"https://secwatch.observer/filing/0001558370-25-007664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/0001558370-25-007664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/kala-20250514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:24:04.698024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}